1
|
Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells. Pharmaceuticals (Basel) 2021; 14:ph14040317. [PMID: 33915981 PMCID: PMC8066102 DOI: 10.3390/ph14040317] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 03/27/2021] [Accepted: 03/29/2021] [Indexed: 11/17/2022] Open
Abstract
New unsymmetrical bisacridines (UAs) demonstrated high activity not only against a set of tumor cell lines but also against human tumor xenografts in nude mice. Representative UA compounds, named C-2028, C-2045 and C-2053, were characterized in respect to their physicochemical properties and the following studies aimed to elucidate the role of metabolic transformations in UAs action. We demonstrated with phase I and phase II enzymes in vitro and in tumors cells that: (i) metabolic products generated by cytochrome P450 (P450), flavin monooxygenase (FMO) and UDP-glucuronosyltransferase (UGT) isoenzymes in noncellular systems retained the compound’s dimeric structures, (ii) the main transformation pathway is the nitro group reduction with P450 isoenzymes and the metabolism to N-oxide derivative with FMO1, (iii), the selected UGT1 isoenzymes participated in the glucuronidation of one compound, C-2045, the hydroxy derivative. Metabolism in tumor cells, HCT-116 and HT-29, of normal and higher UGT1A10 expression, respectively, also resulted in the glucuronidation of only C-2045 and the specific distribution of all compounds between the cell medium and cell extract was demonstrated. Moreover, P4503A4 activity was inhibited by C-2045 and C-2053, whereas C-2028 affected UGT1A and UGT2B action. The above conclusions indicate the optimal strategy for the balance among antitumor therapeutic efficacy and drug resistance in the future antitumor therapy.
Collapse
|
2
|
Paluszkiewicz E, Horowska B, Borowa-Mazgaj B, Peszyńska-Sularz G, Paradziej-Łukowicz J, Augustin E, Konopa J, Mazerska Z. Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes. Eur J Med Chem 2020; 204:112599. [PMID: 32736230 DOI: 10.1016/j.ejmech.2020.112599] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 06/14/2020] [Accepted: 06/16/2020] [Indexed: 02/06/2023]
Abstract
New promising unsymmetrical bisacridine derivatives (UAs), have been developed. Three groups including 36 compounds were synthesized by the condensation of 4-nitro or 4-methylacridinone, imidazoacridinone and triazoloacridinone derivatives with 1-nitroacridine compounds linked with an aminoalkyl chain. Cytotoxicity screening revealed the high potency of these compounds against several tumor cell lines. Particularly, imidazoacridinone-1-nitroacridine dimers strongly inhibited pancreatic Panc-1, Mia-Pa-Ca-2, Capan-2 and prostate cancer DU-145 cell growth. The studied compounds showed very strong antitumor activity (T/C> 300%) against Walker 256 rat adenocarcinoma. The selected 26 UAs were tested against 12 human tumor xenografts in nude mice, including colon, breast, prostate and pancreatic cancers. The studies on the molecular mechanism of action demonstrated that these unsymmetrical dimers significantly responded to the presence of G-quadruplex not to dsDNA. Structure-activity relationships for UAs potency to G-quadruplex stabilization indicated that thermal stability of this drug-G-quadruplex complex depended not only on the structure of heterocyclic rings, but also on the properties of dialkylamino chains of the ring linkers. In conclusion, the presented studies identified the new group of effective antitumor agents against solid human tumors, particularly pancreatic Panc-1, BxPC-3 and Mia-Pa-Ca-2 and strongly indicated their distinctive interactions with DNA. In contrast to monomers, G-quadruplex not dsDNA is proposed to be the first molecular target for these compounds.
Collapse
Affiliation(s)
- Ewa Paluszkiewicz
- Chemical Faculty, Gdańsk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Narutowicza 11/12 Str., 80-233, Gdańsk, Poland
| | - Barbara Horowska
- Chemical Faculty, Gdańsk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Narutowicza 11/12 Str., 80-233, Gdańsk, Poland
| | - Barbara Borowa-Mazgaj
- FDA National Center for Toxicological Research, Biochemical Toxicology, Jefferson, United States
| | - Grażyna Peszyńska-Sularz
- Tri-City Central Animal Laboratory - Research and Service Centre, Medical University of Gdańsk, Dębinki 1 Str., 80-211, Gdańsk, Poland
| | - Jolanta Paradziej-Łukowicz
- Tri-City Central Animal Laboratory - Research and Service Centre, Medical University of Gdańsk, Dębinki 1 Str., 80-211, Gdańsk, Poland
| | - Ewa Augustin
- Chemical Faculty, Gdańsk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Narutowicza 11/12 Str., 80-233, Gdańsk, Poland
| | - Jerzy Konopa
- Chemical Faculty, Gdańsk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Narutowicza 11/12 Str., 80-233, Gdańsk, Poland
| | - Zofia Mazerska
- Chemical Faculty, Gdańsk University of Technology, Department of Pharmaceutical Technology and Biochemistry, Narutowicza 11/12 Str., 80-233, Gdańsk, Poland.
| |
Collapse
|